Eli Lilly and Company $LLY Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 309,267 shares of the company’s stock after selling 12,015 shares during the period. Janney Montgomery Scott LLC’s holdings in Eli Lilly and Company were worth $235,971,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Eli Lilly and Company by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after buying an additional 1,183,038 shares during the last quarter. Laurel Wealth Advisors LLC grew its holdings in Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after acquiring an additional 11,537,661 shares during the period. Norges Bank purchased a new position in Eli Lilly and Company during the second quarter valued at approximately $8,827,714,000. Jennison Associates LLC lifted its holdings in Eli Lilly and Company by 4.3% in the second quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock valued at $4,246,596,000 after acquiring an additional 226,620 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in Eli Lilly and Company by 2.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock worth $4,178,010,000 after purchasing an additional 103,119 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,080.92 on Tuesday. The company has a market cap of $1.02 trillion, a P/E ratio of 52.88, a P/E/G ratio of 0.77 and a beta of 0.35. The company’s 50-day moving average price is $1,040.85 and its 200-day moving average price is $863.67. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business’s revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the business earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is 29.35%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Nvidia co‑innovation AI lab — Nvidia and Lilly will commit up to $1 billion over five years to a San Francisco‑area AI drug discovery lab that will run Nvidia’s newest Vera Rubin AI chips; the partnership could speed candidate discovery, improve R&D productivity and lower time‑to‑market for future programs. Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab
• Positive Sentiment: Management says orforglipron supply is ready — Lilly told investors it’s confident in pill supply ahead of expected U.S. approval, reducing a near‑term execution risk that would otherwise pressure launches and early sales. Lilly says it’s confident weight-loss pill supply ahead of U.S. approval
• Positive Sentiment: Ventyx acquisition adds inflammation program that could complement GLP‑1 franchise — Investors cheered Lilly’s deal for Ventyx (adds VTX3232 data showing inflammation benefit with GLP‑1), which could become an add‑on therapy and extend addressable market for Lilly’s weight‑loss/diabetes drugs.
• Neutral Sentiment: Aktis Oncology stake and biotech deal exposure — Lilly anchored Aktis’ IPO and holds a meaningful equity/stake that gives exposure to targeted radiopharma programs; strategic but long‑dated and dependent on clinical milestones. Aktis Oncology aims to raise up to $317.7 million in IPO
• Neutral Sentiment: Analyst/coverage pieces highlight growth case and new tech investments — Multiple outlets and analysts are reiterating Lilly’s growth story (tirzepatide momentum, pipeline upside) and noting Lilly is building advanced compute/supercomputer capacity; that supports a bullish narrative but is forward‑looking. Here’s Why Eli Lilly (LLY) is a Strong Growth Stock
• Negative Sentiment: Competition from Novo Nordisk’s Wegovy Pill — Novo’s U.S. roll‑out of an oral Wegovy competitor raises market‑share risk for Lilly’s upcoming orforglipron launch and is a clear near‑term competitive headwind priced by investors. Novo Nordisk launches Wegovy Pill in the U.S.

Wall Street Analyst Weigh In

LLY has been the subject of several recent research reports. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, December 19th. Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a research report on Tuesday, December 2nd. Deutsche Bank Aktiengesellschaft increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. HSBC restated a “hold” rating and issued a $1,070.00 price target on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Finally, Bank of America lowered their price target on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a research report on Monday, December 15th. Five equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $1,169.00.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.